Shares of Editas Medicine Inc. (NASDAQ:EDIT) traded up 3.7% on Wednesday . The company traded as high as $28.24 and last traded at $28.08, with a volume of 58,440 shares traded. The stock had previously closed at $27.08.

A number of analysts have recently weighed in on the stock. Zacks Investment Research raised shares of Editas Medicine from a “sell” rating to a “hold” rating in a report on Tuesday, July 19th. Cowen and Company reaffirmed a “buy” rating on shares of Editas Medicine in a report on Monday, May 16th. Vetr raised shares of Editas Medicine from a “hold” rating to a “buy” rating and set a $32.50 price target for the company in a report on Monday, May 9th. Finally, Jefferies Group reissued a “hold” rating and issued a $35.00 price objective on shares of Editas Medicine in a research note on Friday, June 10th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $33.50.

The stock’s 50-day moving average is $26.99 and its 200 day moving average is $30.18. The firm’s market capitalization is $940.09 million.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Monday, May 16th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.30) by $0.50. The firm had revenue of $0.80 million for the quarter, compared to analysts’ expectations of $1.08 million. On average, equities analysts predict that Editas Medicine Inc. will post ($2.35) earnings per share for the current year.

Editas Medicine, Inc, formerly Gengine, Inc, is a genome editing company. The Company is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated protein 9 (Cas9) technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.